Why Wall Street Analysts Are Closely Watching Sanofi (SNY)

Sanofi (NASDAQ:SNY) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Sanofi (NASDAQ:SNY) has a ‘Buy’ or equivalent rating from the majority of the analysts covering the stock. With a one-year median price target of $61, the stock has an upside potential of 23.16%.

According to TheFly, BofA reduced the price target on Sanofi (NASDAQ:SNY) to EUR 102 from EUR 115 on December 1, while keeping a ‘Buy’ rating on the stock.

On December 4, Sanofi (NASDAQ:SNY) disclosed the completion of its acquisition of Vicebio Ltd., which is expected to not only bring an early-stage combination vaccine candidate for two respiratory viruses but also advance its capabilities in vaccine design and development through Vicebio’s Molecular Clamp technology. According to the press release, this acquisition will strengthen Sanofi’s position in respiratory vaccines and allow the company to deliver improved physician and patient choice.

Earlier on November 25, Sanofi (NASDAQ:SNY) and Regeneron announced that the European Commission approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in the EU. This approval, based on phase 3 studies, is anticipated to fortify the company’s foothold in the immunology market.

Sanofi (NASDAQ:SNY), founded in 1994, is a French pharmaceutical company. The company delivers medicines and vaccines for immunology and inflammation, oncology, and other indications.

While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.